Phase I interaction study of docetaxel with supplementation of St. John's wort or Echinacea
Phase 1
- Conditions
- Cancer
- Registration Number
- JPRN-UMIN000009427
- Lead Sponsor
- The Netherlands Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
- Any treatment with investigation drugs within 30 days before the start of the study - Concomitant use of MDR and CYP3A modulating drugs - Unresolved (>grade 1) toxicities of previous chemotherapy - Chronic use of H2-receptor antagonists or proton pump inhibitors - Use of herbal supplements, especially St. John's wort or Echinacea, within 6 weeks prior to study treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method